Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Innoviva Inc
(NQ:
INVA
)
19.15
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Innoviva Inc
< Previous
1
2
Next >
Innoviva to Participate in the UBS Global Healthcare Conference
November 12, 2024
From
Innoviva, Inc.
Via
Business Wire
Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress
November 06, 2024
From
Innoviva, Inc.
Via
Business Wire
Innoviva to Participate in Upcoming Investor Conferences
September 04, 2024
From
Innoviva, Inc.
Via
Business Wire
Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress
July 31, 2024
From
Innoviva, Inc.
Via
Business Wire
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024
From
Innoviva, Inc.
Via
Business Wire
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
May 08, 2024
From
Innoviva, Inc.
Via
Business Wire
Innoviva to Participate in the BofA Securities Health Care Conference
May 08, 2024
From
Innoviva, Inc.
Via
Business Wire
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
April 24, 2024
From
Innoviva Specialty Therapeutics
Via
Business Wire
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
February 29, 2024
From
Innoviva, Inc.
Via
Business Wire
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 01, 2023
From
Innoviva, Inc.
Via
Business Wire
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
November 01, 2023
From
Innoviva Specialty Therapeutics
Via
Business Wire
Innoviva to Participate in the Cantor Global Healthcare Conference
September 19, 2023
From
Innoviva, Inc.
Via
Business Wire
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
September 18, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Appoints Stephen Basso as Chief Financial Officer
August 25, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 02, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference
June 06, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
May 23, 2023
From
Innoviva, Inc.
Via
Business Wire
Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases
May 11, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 09, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Announces Retirement of Board Chairman
April 28, 2023
From
Innoviva, Inc.
Via
Business Wire
Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
April 17, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Stock Trading Halted Today
April 17, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
March 13, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
February 28, 2023
From
Innoviva, Inc.
Via
Business Wire
Four Undervalued Healthcare Stocks for 2023
January 06, 2023
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.
Via
MarketBeat
Exposures
COVID-19
Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
November 30, 2022
From
Innoviva, Inc.
Via
Business Wire
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 09, 2022
From
Innoviva, Inc.
Via
Business Wire
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022
October 19, 2022
--- Presentations Reinforce Topline Safety and Efficacy Findings and Highlight Consistency between Clinical and Microbiological Endpoints
From
Entasis Therapeutics Holdings Inc.
Via
GlobeNewswire
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022
October 12, 2022
Six abstracts selected for presentation, including three oral presentations
From
Entasis Therapeutics Holdings Inc.
Via
GlobeNewswire
Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 08, 2022
From
Innoviva, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.